Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
JAGX logo JAGX
Upturn stock ratingUpturn stock rating
JAGX logo

Jaguar Animal Health Inc (JAGX)

Upturn stock ratingUpturn stock rating
$2.07
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: JAGX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $28

1 Year Target Price $28

Analysts Price Target For last 52 week
$28 Target price
52w Low $1.93
Current$2.07
52w High $35.25

Analysis of Past Performance

Type Stock
Historic Profit -85.84%
Avg. Invested days 17
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.96M USD
Price to earnings Ratio -
1Y Target Price 28
Price to earnings Ratio -
1Y Target Price 28
Volume (30-day avg) 2
Beta 0.44
52 Weeks Range 1.93 - 35.25
Updated Date 08/15/2025
52 Weeks Range 1.93 - 35.25
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -60.27

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -425.52%

Management Effectiveness

Return on Assets (TTM) -37.48%
Return on Equity (TTM) -459.52%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 36608870
Price to Sales(TTM) 0.34
Enterprise Value 36608870
Price to Sales(TTM) 0.34
Enterprise Value to Revenue 3.17
Enterprise Value to EBITDA -0.63
Shares Outstanding 1914430
Shares Floating 990679
Shares Outstanding 1914430
Shares Floating 990679
Percent Insiders 8.15
Percent Institutions 4.56

ai summary icon Upturn AI SWOT

Jaguar Animal Health Inc

stock logo

Company Overview

overview logo History and Background

Jaguar Animal Health Inc. was a commercial stage animal health company focused on developing and commercializing novel, prescription pharmaceuticals derived from sustainably harvested plants from rainforest regions. It appears to have ceased operations or significantly altered its business model as it is no longer actively trading under its previous ticker symbol.

business area logo Core Business Areas

  • Pharmaceuticals for Animals: Development and commercialization of prescription pharmaceuticals for gastrointestinal and inflammatory disorders in animals, particularly focused on dogs and horses.

leadership logo Leadership and Structure

Information regarding the specific leadership and organizational structure prior to ceasing operations is difficult to obtain. Public information would be required to discern specific roles.

Top Products and Market Share

overview logo Key Offerings

  • Canaleviau00ae: A drug approved for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Market share data is unavailable due to the company's current status. Competitors for anti-diarrheal medications in dogs include Zoetis and Boehringer Ingelheim.
  • Neonormu2122 Calf: A product indicated for the supportive treatment of diarrhea in calves. Market share data is unavailable. Competitors include companies offering electrolyte and antibiotic treatments for calf diarrhea.

Market Dynamics

industry overview logo Industry Overview

The animal health industry is a growing market driven by increasing pet ownership, rising disposable incomes, and a greater focus on animal welfare. The pharmaceutical segment is competitive, with established players and emerging companies.

Positioning

Prior to ceasing active operations, Jaguar Animal Health aimed to carve a niche with plant-derived pharmaceuticals. The advantage would have been the natural derivation. The disadvantage being the competition from large, established players.

Total Addressable Market (TAM)

TAM estimates for the animal health pharmaceutical market vary depending on the specific segment (e.g., companion animals vs. livestock). The overall TAM is in the tens of billions of dollars. Given Jaguar's niche focus, their potential TAM would have been a smaller fraction of this total. Positioned to address gastrointestinal disorders.

Upturn SWOT Analysis

Strengths

  • Novel plant-based pharmaceuticals
  • Potential for a natural/organic brand image
  • Approved products for specific indications

Weaknesses

  • Limited financial resources
  • Small market share compared to major players
  • Dependence on single product lines

Opportunities

  • Expanding distribution channels
  • Developing new indications for existing products
  • Strategic partnerships or acquisitions

Threats

  • Competition from established pharmaceutical companies
  • Regulatory hurdles for new drug approvals
  • Potential for generic versions of existing products

Competitors and Market Share

competitor logo Key Competitors

  • ZOET (Zoetis Inc.)
  • MRK (Merck & Co., Inc.)
  • BMY (Bristol-Myers Squibb)

Competitive Landscape

Jaguar Animal Health was at a disadvantage compared to established players with greater resources and wider product portfolios. Its niche focus and plant-based approach provided some differentiation, but ultimately, it was not enough to sustain the business.

Growth Trajectory and Initiatives

Historical Growth: Historical growth was limited due to financial constraints and competitive pressures.

Future Projections: Future projections are not applicable.

Recent Initiatives: Recent strategic initiatives are unknown.

Summary

Jaguar Animal Health faced significant challenges in a competitive market, struggling to achieve sustainable growth and profitability. It aimed to leverage plant-derived pharmaceuticals but ultimately couldn't compete with larger, more established players. Financial difficulties and competitive pressures contributed to its current state. The company will have to overcome fundamental structural difficulties. Due Diligence is required to determine the reason for failure.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Public filings (historical)
  • Industry reports
  • Company websites (historical)

Disclaimers:

The information provided is based on available data and may not be entirely accurate due to the company's status. This is not financial advice. Conduct thorough due diligence before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Jaguar Animal Health Inc

Exchange NASDAQ
Headquaters San Francisco, CA, United States
IPO Launch date 2015-05-13
Founder, CEO, President & Director Ms. Lisa A. Conte
Sector Healthcare
Industry Biotechnology
Full time employees 49
Full time employees 49

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.